Immunoglobulin variable domains
AssigneeAblynx N.V.
InventorsMarie-Ange Buyse, Carlo Boutton
Life of this patent
Estimating the term…
Loading patent…
AssigneeAblynx N.V.
InventorsMarie-Ange Buyse, Carlo Boutton
Estimating the term…
VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
-72. (canceled)
A polypeptide comprising a first immunoglobulin single variable domain (ISVD) that specifically binds to human serum albumin and a second ISVD that specifically binds to a therapeutic target, wherein the second ISVD is at the C-terminal end of the polypeptide and comprises an amino acid V at Kabat position 11 and an amino acid L at Kabat position 89, and wherein the polypeptide has reduced binding to its C-terminal region by pre-existing antibodies found in blood or serum samples obtain from human subjects.
Dependencies are inferred from the claim text.